Low back pain with no identified underlying cause is categorised as primary musculoskeletal pain by the International Association for the Study of Pain. In April 2021, the National Institute for Care and Excellence (NICE) published updated guidance for the management of primary chronic pain conditions in England. As part of the De-STRESS pain study, we explored the perspectives of GPs on the updated guideline and impact upon clinical practice. Semi-structured interviews were conducted with 21 GPs in England. Data were analysed using thematic analysis and constant comparison techniques. GPs agreed with the recommendations restricting pharmacological options for pain management and reflected that they now had an expert reference to back-up their decision-making and could use the guidance in potentially difficult conversations with patients. Frustration was expressed by GPs about the lack of alternative options to medication, as the non-pharmacological recommendations were difficult to implement, had lengthy waiting lists, or were unavailable in their locality.Background and study purpose
Methods and results
Low mood and distress are commonly reported with by people with persistent musculoskeletal pain and may be mislabelled as ‘depression’. In order to understand how pain-related distress is conceptualised and managed in primary care consultations, we explored understanding of pain-related distress and depression from the perspectives of people with persistent musculoskeletal pain and general practitioners (GPs). Semi-structured interviews with 21 GPs and 21 people with persistent musculoskeletal pain were conducted. The majority of people with pain had back pain (15/21). Data were analysed thematically using constant comparison techniques. Participants described challenges distinguishing between distress and depression in the context of persistent pain but described strategies to make this distinction. Some people with pain described how acceptance of their situation was key, involving optimism about the future and creation of a new identity. Some GPs expressed ‘therapeutic nihilism’, with uncertainty about the cause of pain and thus how to manage people with both pain and distress, whilst GPs who could identify and build on optimism with patients described how this could help the patient to move forwards.Background and study purpose
Method and results
The application of artificial intelligence (A.I) using patient reported outcomes (PROs) to predict benefits, risks, benefits and likelihood of improvement following surgery presents a new frontier in shared decision-making. The purpose of this study was to assess the impact of an A.I-enabled decision aid versus patient education alone on decision quality in patients with knee OA considering total knee replacement (TKR). Secondarily we assess impact on shared decision-making, patient satisfaction, functional outcomes, consultation time, TKR rates and treatment concordance. We performed a randomized controlled trial involving 130 new adult patients with OA-related knee pain. Patients were randomized to receive the decision aid (intervention group, n=65) or educational material only (control group, n=65) along with usual care. Both cohorts completed patient surveys including PROs at baseline and between 6–12 weeks following initial evaluation or TKR. Statistical analysis included linear mixed effect models, Mann-Whitney U tests to assess for differences between groups and Fisher's exact test to evaluate variations in surgical rates and treatment concordance.Introduction
Methods
1. That viruses may be involved in the causation of human tumours has long been suspected but not yet proved. The discovery that osteogenic sarcoma can be induced by viral agents in mice and hamsters makes the proposition that human sarcomas may also have a viral origin basically tenable on presently available evidence. In order to distinguish between passengers and causative agents it will probably be necessary to demonstrate antigenic cross-reactivity in tumours of similar type collected from different geographical areas, and the oncogenicity in subhuman primates of extracts containing virus from human tumours. Such information is likely to become available in the next few years. 2. The demonstration of tumour-specific immune reactions in an increasing number of patients with various forms of neoplasm, including skeletal sarcomas, and the correlation of these reactions with the clinical status of the disease sustains the hope that eventually immunotherapy may contribute to the control of cancer in man. 3. Animal experiments have revealed that the potentiation of immune responses may lead to the elimination of small foci of neoplastic cells. The role of immunotherapy in the treatment of cancer may therefore be as an adjunct to surgery, radiotherapy and chemotherapy (Alexander 1968). Once the primary tumour has been removed it may be possible to employ immunotherapeutic measures to destroy the relatively few remaining cells that give rise to late metastases; this is particularly apposite to juvenile osteosarcoma.
